BG
ANIP icon

BlackRock Group’s ANI Pharmaceuticals ANIP Stock Holding History

BlackRock Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$853K Buy
14,066
+5,192
+59% +$317K ﹤0.01% 2199
2016
Q3 		$589K Buy
8,874
+1,242
+16% +$77.7K ﹤0.01% 2259
2016
Q2 		$426K Buy
7,632
+495
+7% +$24.1K ﹤0.01% 2324
2016
Q1 		$241K Buy
7,137
+798
+13% +$27.1K ﹤0.01% 2508
2015
Q4 		$286K Buy
6,339
+160
+3% +$6.89K ﹤0.01% 2411
2015
Q3 		$244K Sell
6,179
-233
-4% -$13.3K ﹤0.01% 2464
2015
Q2 		$398K Buy
6,412
+2,520
+65% +$150K ﹤0.01% 2347
2015
Q1 		$243K Buy
+3,892
New +$237K ﹤0.01% 2429

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

BlackRock Group's ANIP Position: Q4 2016 in Review

BlackRock Group increased its ANI Pharmaceuticals (ANIP) stake by 59% in Q4 2016, buying an estimated $317K and bringing the position to 14,066 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #2199.

BlackRock Group first reported a position in ANIP in Q1 2015 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

  • BlackRock Group held 14,066 shares of ANI Pharmaceuticals worth $853K as of Q4 2016.
  • BlackRock Group bought 5,192 ANI Pharmaceuticals shares in Q4 2016, an estimated $317K.
  • ANI Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2199 holding.
  • BlackRock Group first reported a position in ANI Pharmaceuticals in Q1 2015 and has held it in 8 quarters since.
  • 157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.